Quantitative analysis revealed that SA achieved an impressive tumor growth inhibition (TGI) rate of 88.72%, representing a substantial improvement over the conventional anti-PD-L1 antibody treatment, which yielded a TGI of 66.97% (Figure 4B). Here, CD274 is linked to neoplasm.